How much weight can you expect to lose on a GLP‑1 medication

Introduction

One of the first questions people ask about GLP‑1 medications is how much weight they can realistically lose. Whether you are considering semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), clinical trial data offers helpful benchmarks, though individual results vary significantly.

What clinical trials show

Large-scale clinical trials have measured average weight loss across thousands of participants:

• Wegovy (semaglutide 2.4 mg): Participants in the STEP 1 trial lost an average of 14.9% of their body weight over 68 weeks. For someone starting at 220 pounds, that is approximately 33 pounds.
• Ozempic (semaglutide 1 mg): Originally approved for type 2 diabetes, Ozempic produces average weight loss of 8 to 14 pounds over 30 weeks at the 1 mg dose in the SUSTAIN trials.
• Mounjaro (tirzepatide 15 mg): In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks. That translates to roughly 50 pounds for someone starting at 220 pounds.
• Zepbound (tirzepatide 15 mg): The same active ingredient as Mounjaro, approved specifically for weight management, with similar results from the SURMOUNT trial data.

These numbers represent averages. Some participants lost significantly more, while others lost less.

Why results vary from person to person

Your individual results depend on several factors beyond the medication itself:

• Starting weight: People with more weight to lose often see larger absolute losses early on.
• Dose level: Higher doses generally produce more weight loss, which is why titration schedules gradually increase your dose.
• Diet and exercise: GLP‑1 medications work best alongside healthy eating and regular physical activity.
• Metabolic factors: Insulin resistance, thyroid function, and other hormonal factors affect how quickly you respond.
• Medication adherence: Missing doses or inconsistent timing can reduce effectiveness.

What a realistic timeline looks like

Weight loss on GLP‑1 medications is not linear. Most people experience a common pattern:

• Weeks 1 to 4: Modest initial loss, mostly driven by reduced appetite. Nausea may limit food intake during this period.
• Months 2 to 6: The most active weight loss phase. Most people see steady weekly losses as doses increase during titration.
• Months 6 to 12: Weight loss typically slows as your body adapts. This is normal, not a sign the medication has stopped working.
• Month 12 and beyond: Many people reach a plateau or enter a maintenance phase. Continued use helps sustain the weight already lost.

Setting healthy expectations

It helps to think about GLP‑1 weight loss in terms of percentages rather than specific pound targets. A loss of 10 to 15% of your starting body weight is considered clinically meaningful and is associated with improvements in blood pressure, blood sugar, cholesterol, and joint health. Not everyone will reach the trial averages, and that is perfectly fine. Even modest weight loss brings real health benefits.

Track your weight loss with Shotsy

Shotsy’s weight charts show your total weight change by dose level, so you can see exactly how each dose adjustment has contributed to your progress. The average weekly weight loss by dose chart helps you set realistic expectations, and the color-coded weight trend gives you a clear picture of your journey over time.

Conclusion

Clinical trials show that GLP‑1 medications can produce meaningful weight loss, averaging 10 to 22% of body weight depending on the medication and dose. Your individual results depend on many factors, so focus on steady progress rather than hitting a specific number. Consistent tracking helps you and your provider make informed decisions along the way.